Scisparc Stock Today
| SPRC Stock | USD 0.60 0.01 1.64% |
PerformanceWeakest
| Odds Of DistressLow
|
Scisparc is trading at 0.6 as of the 15th of February 2026, a 1.64 percent decrease since the beginning of the trading day. The stock's open price was 0.61. Scisparc has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of November 2025 and ending today, the 15th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of August 2021 | Category Healthcare | Classification Health Care |
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Scisparc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 5.09 M outstanding shares of which 176.03 K shares are at this time shorted by private and institutional investors with about 0.08 trading days to cover. More on Scisparc
Moving together with Scisparc Stock
Moving against Scisparc Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Scisparc Stock Highlights
| President Director | Itschak Shrem | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Stock Exchange Of, SET100 Index, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, Scisparc can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Scisparc's use of financial leverage and reveals what portion of Scisparc's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Scisparc (SPRC) is traded on NASDAQ Exchange in USA and employs 2 people. Scisparc is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.04 M. Scisparc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 5.09 M outstanding shares of which 176.03 K shares are at this time shorted by private and institutional investors with about 0.08 trading days to cover.
Scisparc currently holds about 6.88 M in cash with (5.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Scisparc Probability Of Bankruptcy
Ownership AllocationScisparc maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Scisparc Ownership Details
Scisparc Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sbi Securities Co Ltd | 2025-06-30 | 385 | |
| Bank Of America Corp | 2025-06-30 | 42.0 | |
| Rhumbline Advisers | 2025-06-30 | 16.0 | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 5.0 | |
| Susquehanna International Group, Llp | 2025-03-31 | 0.0 | |
| Jpmorgan Chase & Co | 2025-03-31 | 0.0 | |
| Two Sigma Securities, Llc | 2025-06-30 | 0.0 | |
| Ubs Group Ag | 2025-03-31 | 0.0 |
Scisparc Historical Income Statement
Scisparc Stock Against Markets
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scisparc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Scisparc Stock refer to our How to Trade Scisparc Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could Scisparc diversify its offerings? Factors like these will boost the valuation of Scisparc. If investors know Scisparc will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Scisparc data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 350.73 | Revenue Per Share | Quarterly Revenue Growth (0.45) | Return On Assets | Return On Equity |
Understanding Scisparc requires distinguishing between market price and book value, where the latter reflects Scisparc's accounting equity. The concept of intrinsic value - what Scisparc's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Scisparc's price substantially above or below its fundamental value.
Please note, there is a significant difference between Scisparc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scisparc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Scisparc's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.